Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 6, 2008, Pages 513-520

  Yaziji, Hadi ^a   Taylor, Clive R ^b   Goldstein, Neal S ^d   Dabbs, David J ^e   Hammond, Elizabeth H ^f   Hewlett, Bryan ^o   Floyd, Alton D ^a   Barry, Todd S ^c   Martin, Alvn W ^g   Badve, Sunil ^h   Baehner, Frederick ^h   Cartun, Richard W ⁱ   Eisen, Richard N ^j   Swanson, Paul E ^k   Hewitt, Stephen M ^l   Vyberg, Mogen ⁿ   Hicks, David G ^m  

^a Vitro Molecular Laboratories   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Clarient   (United States)

^d Advanced Diagnostics Laboratory   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f LDS HOSPITAL   (United States)

^g University of Louisville School of Medicine   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ HARTFORD HOSPITAL   (United States)

^j GREENWICH HOSPITAL   (United States)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

ⁿ NordiQC   (Denmark)

^o Qual Mgmt Program Laboratory Serv   (Canada)

more..

Author keywords

Breast cancer; ER; Estrogen receptor; IHC; Immunohistochemistry; Standardization

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ASPIRATION BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CONSENSUS; DIAGNOSTIC PROCEDURE; FALSE NEGATIVE RESULT; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; PATHOLOGIST; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIAGNOSTIC ERROR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; METABOLISM; METHODOLOGY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; STANDARD; TISSUE FIXATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIAGNOSTIC ERRORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ESTROGEN; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TAMOXIFEN; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 67650284116     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31818a9d3a     Document Type: Review

References (28)

1. Moore A. Breast-cancer therapy-looking back to the future. N Engl J Med. 2007;357:1547-1549.
2. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14:2843-2877.
3. Rhodes A, Jasani B, Balaton AJ, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000;53:688-696. (Pubitemid 30692408)
4. Rhodes A, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol. 2001;115:44-58. (Pubitemid 33695090)
5. Layfield LJ, Goldstein N, Perkinson KR, et al. Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J. 2003;9:257-259. (Pubitemid 36627180)
6. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120: 86-92. (Pubitemid 37046374)
7. Hammond EH. 2007: In Reply. Arch Pathol Lab Med. 2007;131: 1510-1511.
8. Burnett MG. The mechanism of the formaldehyde clock reaction: Methylene glycol dehydration. J Chem Educ. 1982;59:160.
9. Fox CH, Johnson FB, Whiting J, et al. Formaldehyde fixation. J Histochem Cytochem. 1985;33:845-853.
10. Helander KG. Kinetic studies of formaldehyde binding in tissue. Biotech Histochem. 1994;69:177-179.
11. Helander KG. Formaldehyde binding in brain and kidney: a kinetic study of fixation. J Histotechnol. 1999;22:317-318.
12. Taylor CR. Immunomicroscopy: A Tool for the Surgical Pathologist. Philadelphia, PA: WB Saunders; 1986:48-49.
13. Sternberger LA. Immunohistochemistry. 3rd ed. 1986:212.
14. Floyd AD, Yaziji H. Process control for standardization of multiple step staining protocols. Arch Pathol Lab Med. 2008;132: 870-871.
15. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
16. Grimes R, Saiz E, Sanchez B, et al. Successful design of low-level estrogen receptor positive tissue controls for critical quality control measures. Mod Pathol. 2008;1:34A.
17. Pertschuk LP, Feldman JG, Kim YD, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996;77:2514-2519. (Pubitemid 26169148)
18. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637-5644.
19. Shoker BS, Jarvis C, Clarke RB, et al. Estrogen receptor-positive proliferating cell in the normal and precancerous breast. Am J Pathol. 1999;155:1811-1815.
20. Tremblay G, Deschenes J, Alpert L, et al. Overexpression of estrogen receptors in columnar cell change and in unfolding breast lobules. Breast J. 2005;11:326-332. (Pubitemid 41726035)
21. Paik S, Tang G, Shak S, et al. Gene expression and benefit chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol. 2006;24:3726-3734. (Pubitemid 46622311)
22. Badve SS, Baehner FL, Gray RP, et al. Estrogen and progesterone receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473-2481.
23. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr. 2001;30:5-15. Review.
24. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004;6:240-245. (Pubitemid 39440252)
25. Allred DC, Mohsin SK. ER expression is not bimodal in breast cancer. Am J Clin Pathol. 2005;124:474-476.
26. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350-7360.
27. Rakha EA, El-Sayed ME, Reis-Filho JS, et al. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology. 2008;52:67-81.
28. Taylor CR. Viewpoint: an exaltation of experts: concerted efforts in the standardization of immunohistochemistry. Applied Immunohistochem. 1993;1:232-243.